Adrian M. Senderowicz, M.D.
Dr. Senderowicz was appointed as a director of Puma Biotechnology on August 11, 2015. Dr. Senderowicz served
as Senior Vice President and Chief Medical Officer at Constellation Pharmaceuticals, a clinical-stage
biopharmaceutical company focused on the development of novel tumor-targeted and immuno-oncology therapies,
from July 2017 to June 2020.
Prior to joining Constellation, Dr Senderowicz served as Senior Vice President and Chief Medical Officer at Cerulean
Pharma, Inc., a public clinical-stage company developing nano-particle conjugates, from September 2015 to June
2017. Prior to joining Cerulean, Dr. Senderowicz served as Chief Medical Officer and Senior Vice President, Clinical
Development and Regulatory Affairs from August 2014 to February 2015, and Clinical and Regulatory Strategy
Officer from February 2015 to April 2015 of Ignyta, Inc., a public precision oncology biotechnology company.
Previously, Dr. Senderowicz was Vice President, Global Regulatory Oncology at Sanofi, a position he held from
September 2013 to August 2014. Prior to Sanofi, he was Chief Medical Officer and Vice President, Medical
Development at Tokai Pharmaceuticals, Inc. from August 2012 to March 2013. From August 2008 to March 2012, he
held positions of increasing responsibility, including Senior Medical Director, Oncology Clinical Development, at
AstraZeneca. Before his tenure at AstraZeneca, Dr. Senderowicz spent almost four years in a variety of leadership
positions at the U.S. Food and Drug Administration Division of Oncology Drug Products in the Center for Drug
Evaluation and Research. Prior to his work with the FDA, he held a variety of clinical and research positions,
including Coordinator of the Prostate Cancer Drug Development Clinic and Investigator and Chief, Molecular
Therapeutics Unit, with the National Cancer Institute/National Institutes of Health.
Dr. Senderowicz holds both an M.D. and an Instructor of Pharmacology degree from the School of Medicine at the
Universidad de Buenos Aires in Argentina. Dr. Senderowicz was selected as a director because of his extensive
clinical and regulatory background and his significant experience in the life sciences industry.
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024